Monitoring verified workforce reductions, state WARN Act filings, clinical-readout downsizings, post-merger consolidations, and R&D footprint realignments across global pharmaceutical, clinical-stage biotechnology, and CDMO organizations.
Click any catalyst category to filter the tracker table below
Click a month column to isolate events from that period
Note: May 2026 industry-wide layoffs reached ~6,956 roles (led by Takeda & BioNTech), while September reflects Novo's cumulative 13,000-role global reduction disclosure. July (466 roles, -94% YoY) and August (~500+ roles, -90% YoY) marked multi-year lows.
| Company ▲ | Date ▼ | Workforce Impact ▲ | Primary Catalyst ▲ | Location & Stage ▲ | Details & Clinical Context | Source |
|---|---|---|---|---|---|---|
Artiva Biotherapeutics NASDAQ: ARTV Cell & Gene Therapy | 2026-10-27 | ~108 roles (94%) | Clinical Trial SetbackConfirmed | San Diego, CA, USAPhase 2 | Artiva Biotherapeutics permanently discontinued development of its lead non-genetically modified allogeneic NK cell therapy AlloNK (AB-101) across all autoimmune indications—scrapping a planned Phase 3 rheumatoid arthritis trial—after longer-term Phase 2a clinical response durability fell short and two Grade 5 fatal events occurred (including fatal leukoencephalopathy linked to fludarabine lymphodepletion). Artiva slashed 94% of its ~115-person workforce and engaged Leerink Partners to explore strategic alternatives while holding ~$319.1M in cash. | Fierce Biotech ↗ |
InvaGen Pharmaceuticals (Cipla) NSE: CIPLA Specialty & Generic Pharma | 2026-10-27 | 205 roles (NY WARN) | Corporate Restructuring & Cost ReductionWARN Notice | Central Islip & Hauppauge, NY, USACommercial / Big Pharma | Cipla US subsidiary InvaGen Pharmaceuticals filed New York WARN Act notices to eliminate 205 manufacturing and operations positions across two Long Island facilities—cutting 160 of 408 workers in Central Islip and 45 of 96 workers in Hauppauge—as part of a corporate cost-optimization and portfolio realignment toward complex generics. | Newsday / NY WARN ↗ |
Teva Pharmaceutical Industries NYSE: TEVA Specialty & Generic Pharma | 2026-10-27 | 61 roles (NJ WARN / Plant Closure) | Corporate Restructuring & Cost ReductionWARN Notice | Fairfield, NJ, USACommercial / Big Pharma | Teva Pharmaceutical Industries filed a New Jersey WARN Act notice disclosing 61 layoffs and the permanent closure of its solid oral-dose manufacturing plant in Fairfield, New Jersey by January 31, 2027 (effective February 1, 2027). The facility shutdown is part of CEO Richard Francis's multi-year 'Pivot to Growth' operational realignment, which aims to phase out underutilized, high-overhead production footprints facing generic price erosion while reallocating manufacturing capital toward biosimilars and core commercial brands like Austedo and Ajovy. | Fierce Pharma / NJ WARN ↗ |
Botanix Pharmaceuticals ASX: BOT Dermatology | 2026-10-26 | 60% of workforce | Corporate Restructuring & Cost ReductionConfirmed | Philadelphia, PA, USA & Perth, AustraliaCommercial | Dermatology company Botanix Pharmaceuticals implemented a ~60% headcount reduction to cut FY27 operating expenses by approximately 50% while streamlining commercial operations around its FDA-approved hyperhidrosis treatment Sofdra. | BioSpace ↗ |
Tango Therapeutics NASDAQ: TNGX Oncology & Synthetic Lethality | 2026-10-26 | ~19 roles (14%) | Pipeline Pivot & ReprioritizationConfirmed | Boston, MA, USAPhase 2 | Tango Therapeutics cut 14% of its workforce (~19 discovery roles) and halted novel preclinical target discovery to focus capital on advancing its clinical MTA-cooperative PRMT5 inhibitors—vopimetostat (TNG462) and brain-penetrant TNG456—following ESMO Phase 1/2 pancreatic cancer combination data with Revolution Medicines' RAS(ON) inhibitors. | Fierce Biotech ↗ |
Fractyl Health NASDAQ: GUTS Metabolic & Obesity | 2026-10-22 | ~45 roles (45%) | Pipeline Pivot & ReprioritizationConfirmed | Burlington, MA, USAPivotal / Pre-Commercial | Fractyl Health disclosed in an SEC Form 8-K (Item 2.05) a ~45% workforce reduction (~45 of ~100 employees) and discontinued internal development of its Rejuva AAV pancreatic gene therapy program to cut quarterly cash burn by 50% and focus exclusively on an FDA De Novo marketing submission for its Revita DMR post-GLP-1 weight maintenance procedure. | BioSpace / SEC 8-K ↗ |
| 2026-10-22 | ~480+ roles (~60% in Catania) | Corporate Restructuring & Cost ReductionConfirmed | Catania, Sicily, Italy & Portage, MI / Sanford, NC, USACommercial / Big Pharma | Pfizer initiated early execution of its $2.5B multi-year manufacturing optimization and cost-cutting program, triggering labor union disputes over 330 job cuts (~60% of site staff) and the shuttering of its penicillin production unit in Catania, Sicily, alongside ~150 confirmed layoffs at its Portage, Michigan facility and additional cuts across North Carolina sterile injectables and biologics plants. | Fierce Pharma ↗ | |
Enlivex Therapeutics NASDAQ: ENLV Immunology & Cell Therapy | 2026-10-19 | 60% of workforce | Pipeline Pivot & ReprioritizationConfirmed | Nes-Ziona, IsraelPhase 2 | Macrophage-reprogramming cell therapy developer Enlivex laid off 60% of its workforce and implemented substantial executive salary reductions to extend cash runway around its Allocetra clinical programs. | Fierce Biotech ↗ |
EyePoint Pharmaceuticals NASDAQ: EYPT Ophthalmology | 2026-10-19 | 105 roles (53%) | Clinical Trial SetbackConfirmed | Watertown & Northbridge, MA, USAPhase 3 | Following a second pivotal Phase 3 primary-endpoint miss for DURAVYU (intravitreal vorolanib insert) in wet age-related macular degeneration (wet AMD), EyePoint terminated its late-stage wet AMD trials early, filed Massachusetts WARN notices to cut 105 positions (~53% of staff) across its Watertown and Northbridge facilities, and shifted clinical capital toward diabetic macular edema (DME). | BioSpace / MA WARN ↗ |
| 2026-10-14 | 1,217 roles (14% local) | Corporate Restructuring & Cost ReductionPlanned / Reported | Wavre, Rixensart & Gembloux, BelgiumCommercial / Big Pharma | GSK initiated plans to cut up to 1,217 R&D, management, and support roles (~14% of its Belgian workforce) across its vaccine division hubs in Wavre, Rixensart, and Gembloux under CEO Luke Miels' £1.9B ($2.5B) 'Accelerate Growth' cost-reduction program. | BioSpace ↗ | |
Caribou Biosciences NASDAQ: CRBU Cell & Gene Therapy | 2026-10-06 | 87 roles (90%) | Pipeline Pivot & ReprioritizationWARN Notice | Berkeley, CA, USAPhase 1 | CRISPR pioneer Caribou Biosciences ceased all clinical development across its off-the-shelf allogeneic ex vivo CAR-T pipeline (including vispa-cel and CB-011), laying off 87 of 97 employees (~90% of staff) per California WARN filings to explore strategic alternatives. | Fierce Biotech ↗ |
Aviceda Therapeutics PrivateOphthalmology & Glycobiology | 2026-10-05 | Winding down | Shutdown / BankruptcyWinding Down | Cambridge, MA, USAPhase 2 | Glyco-immunology biotech Aviceda Therapeutics initiated a corporate wind-down of its Cambridge operations following setbacks in its geographic atrophy program AVD-104. | BioSpace ↗ |
Adecto Pharmaceuticals PrivateOncology & Antibody-Drug Conjugates | 2026-10-02 | 100% (Shutdown) | Shutdown / BankruptcyWinding Down | Boston, MA, USAPreclinical | Preclinical oncology and ADC developer Adecto Pharmaceuticals ceased operations and dissolved its team, citing a risk-averse early-stage venture financing environment. | BioSpace ↗ |
Foghorn Therapeutics NASDAQ: FHTX Oncology & Chromatin Biology | 2026-10-01 | 40% of workforce | M&A / Partnership TerminationConfirmed | Cambridge, MA, USAPhase 1 | Chromatin-remodeling oncology developer Foghorn Therapeutics cut 40% of its workforce after Eli Lilly terminated their multi-year oncology research and licensing collaboration; Foghorn is redirecting capital toward its Phase 1 selective SMARCA2 inhibitor FHD-909. | BioSpace ↗ |
BioMarin Pharmaceutical NASDAQ: BMRN Rare Disease & Genetic Medicines | 2026-09-30 | 117 roles | Corporate Restructuring & Cost ReductionWARN Notice | Novato & San Rafael, CA, USACommercial / Big Pharma | BioMarin filed California WARN notices to lay off 117 employees across its Novato and San Rafael facilities as part of an operational footprint consolidation and margin-expansion program. | Fierce Pharma ↗ |
No layoff or restructuring events match your search or filter criteria.
Real-time reporting on biopharma headcount reductions, site closures, and labor trends indexed from our news feed.
Artiva Biotherapeutics halted all clinical development of its lead allogeneic NK cell therapy AlloNK (AB-101), scrapped a planned Phase 3 rheumatoid arthritis trial, and slashed 94% of its workforce after longer-term response durability fell short and two Grade 5 fatal events occurred.
Cipla US subsidiary InvaGen Pharmaceuticals filed New York WARN Act notices to eliminate 205 manufacturing and operations positions across its Central Islip and Hauppauge facilities on Long Island as part of a plant restructuring and portfolio realignment toward complex generics.
Teva Pharmaceutical Industries filed a New Jersey WARN Act notice disclosing 61 layoffs and the permanent closure of its solid oral-dose manufacturing facility in Fairfield, NJ by January 31, 2027, as part of CEO Richard Francis's 'Pivot to Growth' cost-efficiency strategy.
Dermatology developer Botanix Pharmaceuticals announced a corporate restructuring cutting approximately 60% of its workforce and targeting a 50% reduction in FY27 operating expenses while focusing commercial capital on its FDA-approved hyperhidrosis gel Sofdra.
Boston-based Tango Therapeutics laid off 14% of its staff (~19 discovery roles) to halt novel target discovery and concentrate capital on its clinical PRMT5 inhibitors vopimetostat and TNG456 after reporting strong Phase 1/2 pancreatic cancer combination data with Revolution Medicines.
BMS sheds light on patient death in CAR-T trial
Moderna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat
Burlington, Massachusetts-based Fractyl Health is laying off approximately 45% of its staff (~45 roles) and discontinuing internal development of its Rejuva pancreatic gene therapy program to focus resources on an FDA De Novo marketing submission for its Revita post-GLP-1 weight maintenance procedure.
Pfizer confirmed an early rollout of its multi-year $2.5B manufacturing optimization initiative, triggering Italian union disputes over 330 job cuts in Catania, Sicily, alongside ~150 confirmed layoffs at its Portage, Michigan facility and additional cuts at North Carolina plants.
GSK planning 1,200 job cuts in Belgium, says paper
Enlivex lays off 60% of staff, 'substantially' cuts exec pay
EyePoint to halve workforce after experimental drug fails second late-stage trial
Data-driven analyses contrasting workforce reductions with active hiring across Big Pharma, CDMOs, and AI-native biotech.
A day of pipeline discipline and portfolio tidying: Verdiva halts a mid-stage oral GLP-1 study and Biomea's early obesity data leaves investors cold, while GSK confirms 1,200+ Belgium layoffs. Elsewhere, Zealand pays up to $1.2B for AI-designed metabolic drugs, Galderma buys Zo Skin Health for $1.5B, and Liquidia settles its Tyvaso patent fight with United Therapeutics for $380M.
Read Full Analysis →29 items from seven free sources. The day splits three ways: a workforce cluster (Foghorn shedding 40% of staff after its Lilly collaboration collapsed, plus cuts at BioMarin and Novo Nordisk), a regulatory cluster led by an FDA warning letter for a Fresenius Kabi plant and fresh FDA moves on trial modernization and advisory committees, and a business block anchored by Sanofi's $1B upfront payment to Regeneron and Varda's $251M Series D for orbital drug manufacturing.
Read Full Analysis →Wednesday's harvest produced twenty-one items across six sources. Immunovant's IMVT-1402 failed a phase 2b cutaneous lupus study, Roche's phase 3 kidney win opened an accelerated-approval path, and AI-driven discovery pulled in a $311M Series E for Enveda and a $140M Series C for Basecamp Research. Diagnostic and delivery milestones landed from Werfen, Persista Bio and Sagent, while BMS added another 265 New Jersey layoffs and nine European board chairs warned about the bloc's R&D footing.
Read Full Analysis →A data-driven analysis of 2,912 active life-sciences job postings indexed in July 2026 across 88 companies — top hirers, in-demand roles, tech-stack keywords, geographic spread, and what the hiring data tells us about the state of biotech and pharma employment in mid-2026.
Read Full Analysis →Today's harvest from BioSpace, Fierce Pharma, Fierce Biotech, and STAT News surfaces two Amgen stories (FDA appeal for Tavneos, ~40 layoffs) plus a Roche Q2 pipeline update from CEO Schinecker and a Fierce Biotech study flagging genetic risk markers in Yescarta patients.
Read Full Analysis →A daily synthesis of the 39 biopharma news items the OpenBio News harvest cron pulled this morning: FDA approval of Merck's oral PCSK9 inhibitor Lipfendra, two parallel Lilly psychedelic buyouts (AtaiBeckley, ~$2.8-3.8B), projected 14,000+ H1 biopharma layoffs, Sanofi's mRNA-patent suit against Pfizer and Moderna, an FDA screwworm-drug EUA, and the Vogenx and Braveheart IPO filings.
Read Full Analysis →While clinical setbacks and post-merger consolidations drive targeted layoffs, OpenBio News indexes thousands of active GxP, manufacturing, biostatistics, and computational biology openings across 780+ companies.